ZA200801351B - Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors - Google Patents

Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors

Info

Publication number
ZA200801351B
ZA200801351B ZA200801351A ZA200801351A ZA200801351B ZA 200801351 B ZA200801351 B ZA 200801351B ZA 200801351 A ZA200801351 A ZA 200801351A ZA 200801351 A ZA200801351 A ZA 200801351A ZA 200801351 B ZA200801351 B ZA 200801351B
Authority
ZA
South Africa
Prior art keywords
sulphonypyrrole
histone deacetylases
hydrochloride salts
deacetylases inhibitors
inhibitors
Prior art date
Application number
ZA200801351A
Other languages
English (en)
Inventor
Maier Thomas
Beckers Thomas
Hummel Rolf-Peter
Feth Martin
Mueller Matthias
Baer Thomas
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of ZA200801351B publication Critical patent/ZA200801351B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200801351A 2005-09-21 2008-02-08 Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors ZA200801351B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05108716 2005-09-21

Publications (1)

Publication Number Publication Date
ZA200801351B true ZA200801351B (en) 2009-09-30

Family

ID=35810290

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801351A ZA200801351B (en) 2005-09-21 2008-02-08 Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors

Country Status (16)

Country Link
US (1) US8188138B2 (pt)
EP (1) EP1928826B1 (pt)
JP (1) JP5305909B2 (pt)
KR (1) KR101314158B1 (pt)
CN (1) CN101287706A (pt)
AR (1) AR055647A1 (pt)
AU (1) AU2006298881A1 (pt)
BR (1) BRPI0616040A2 (pt)
CA (1) CA2622670A1 (pt)
EA (1) EA018698B1 (pt)
IL (1) IL189781A0 (pt)
NO (1) NO20081796L (pt)
NZ (1) NZ566073A (pt)
TW (1) TWI382971B (pt)
WO (1) WO2007039403A1 (pt)
ZA (1) ZA200801351B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EA012451B1 (ru) * 2004-03-11 2009-10-30 4Сц Аг Новые амидозамещённые гидрокси-6-фенилфенантридины
EP2295426A1 (en) 2004-04-30 2011-03-16 Bayer HealthCare, LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
SI1928872T1 (sl) * 2005-09-21 2012-06-29 4Sc Ag Novi sulfonilpiroli kot inhibitorji HDAC
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
EP2100878A1 (en) 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
AU2013246278B2 (en) 2012-04-10 2016-11-03 Annji Pharmaceutical Co., Ltd. Histone deacetylases (HDAC) inhibitors
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
RU2657783C2 (ru) 2013-09-30 2018-06-15 Тайхо Фармасьютикал Ко., Лтд. Комбинированная терапия с использованием азабициклосоединения для ракового заболевания
CN109496210A (zh) 2016-07-26 2019-03-19 费森尤斯卡比肿瘤学有限公司 贝利司他的多晶型及其制备方法
JP7254028B2 (ja) 2017-05-16 2023-04-07 アンジー ファーマスーティカル シーオー．，エルティーディー． ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤
US20230027247A1 (en) * 2019-12-16 2023-01-26 Edigene (Guangzhou) Inc. Small molecule compounds for amplifying hematopoietic stem cells, and combination thereof
JP2023530788A (ja) 2020-06-08 2023-07-19 アンジー ファーマシューティカル カンパニー リミテッド 選択的ｈｄａｃ６阻害剤として有用なキナゾリン誘導体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
EP0570594B1 (en) 1991-12-10 1997-07-30 Shionogi & Co., Ltd. Hydroxamic acid derivative based on aromatic sulfonamide
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
WO2001038323A1 (en) 1999-11-23 2001-05-31 Merck & Co., Inc. Pyrazinone thrombin inhibitors
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
CN101284773A (zh) 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7482488B2 (en) 2002-08-29 2009-01-27 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
WO2005070900A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
EA012451B1 (ru) * 2004-03-11 2009-10-30 4Сц Аг Новые амидозамещённые гидрокси-6-фенилфенантридины
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
CN101137623B (zh) * 2005-03-15 2013-03-27 奈科明有限责任公司 N-磺酰基吡咯及其作为组蛋白脱乙酰酶抑制剂的用途
WO2006105979A1 (en) 2005-04-07 2006-10-12 Nycomed Gmbh Sulfonylpyrroles as histone deacetylase inhibitors
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
BRPI0615259A2 (pt) * 2005-08-29 2011-05-17 Sanofi Aventis Us Llc forma cristalina de um derivado de piridazino[4,5-b] indol
CN101687905A (zh) * 2005-09-13 2010-03-31 西科尔公司 纯罗库溴铵
SI1928872T1 (sl) * 2005-09-21 2012-06-29 4Sc Ag Novi sulfonilpiroli kot inhibitorji HDAC
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists

Also Published As

Publication number Publication date
TW200745027A (en) 2007-12-16
WO2007039403A1 (en) 2007-04-12
CN101287706A (zh) 2008-10-15
EA200800791A1 (ru) 2009-04-28
AU2006298881A1 (en) 2007-04-12
EP1928826B1 (en) 2013-04-24
BRPI0616040A2 (pt) 2011-06-07
EA018698B1 (ru) 2013-10-30
JP2009508825A (ja) 2009-03-05
US20090297473A1 (en) 2009-12-03
CA2622670A1 (en) 2007-04-12
TWI382971B (zh) 2013-01-21
NZ566073A (en) 2011-08-26
IL189781A0 (en) 2008-08-07
AR055647A1 (es) 2007-08-29
KR20080046730A (ko) 2008-05-27
KR101314158B1 (ko) 2013-10-04
EP1928826A1 (en) 2008-06-11
US8188138B2 (en) 2012-05-29
NO20081796L (no) 2008-04-17
JP5305909B2 (ja) 2013-10-02

Similar Documents

Publication Publication Date Title
ZA200801351B (en) Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors
IL188692A0 (en) Histone deacetylase inhibitors
IL182237A0 (en) New histone deacetylases inhibitors
ZA201002841B (en) Histone deacetylase inhibitors
IL190429A0 (en) Benzamide compounds useful as histone deacetylase inhibitors
IL193458A0 (en) Histone deacetylase inhibitors
TWI371275B (en) Heterocyclic amide compounds as protein kinase inhibitors
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
IL187881A0 (en) Sphingosine kinase inhibitors
IL197752A0 (en) Hdac inhibitors
SI1881976T1 (sl) Substituirani amidni derivati kot inhibitorji protein-kinaz
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
EP2217226A4 (en) Deformylase PEPTIDE INHIBITORS
IL189112A0 (en) NOVEL HETEROCYCLIC NF-kB INHIBITORS
EP1789381A4 (en) INHIBITORS OF HISTONE DEACETYLASE
ZA200806983B (en) Amide derivative or salt thereof
IL198014A0 (en) Heterocyclic derived metalloprotease inhibitors
EP2205563A4 (en) NEW HISTONDEACETYLASE INHIBITORS
ZA201001972B (en) Novel teteahydrofusedpyridines as histone deacetylase inhibitors
GB0700830D0 (en) Crystalline duloxetine hydrochloride
IL193981A0 (en) Novel heterocyclic nf-kb inhibitors
EP1817020A4 (en) INHIBITORS OF HISTONATE ACETYLASE